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INTRODUCTION
The bioactive lipid, sphingosine 1-phosphate (S1P) is formed by the sphingosine kinase-catalyzed
phosphorylation of sphingosine. There are two isoforms of sphingosine kinase termed SphK1 and
SphK2 that are encoded by different genes and which exhibit distinct sub-cellular localization and
biochemical properties to regulate overlapping and non-overlapping biology (1). S1P is either
degraded by S1P lyase to produce (E)-2-hexadecenal and phosphoethanolamine or reversibly
dephosphorylated by S1P phosphatase to regenerate sphingosine (1). S1P can be exported from cells
[through transporter proteins such as Spns2 (2),MFsd2b (3), and someABC proteins (4)] to bind to
a family of five S1P-specific G protein coupled receptors (S1P1−5) (5). There is substantial evidence
to suggest that S1P has a critical role in cancer. For example, the knockout of lymphatic endothelial
Spns2 reduces pulmonarymetastasis via amechanism that involves induction of a lymphopenia and
an increase in effector T cells and natural killer (NK) cells to enhance tumor cell killing in the lung
(6). Other evidence supports a role for S1P in transformation, epithelial mesenchymal transition
(EMT), invasiveness, cancer cell survival and replicative immortality, tumor neovascularisation,
and the Warburg effect (7).
ROLE OF S1P IN DEFINING BREAST CANCER PROGNOSIS
Lei et al. (8) used data mining and the Kaplan-Meier plotter (http://kmplot.com/analysis/index.
php?p=service&cancer=breast) to establish relationships between messenger RNA levels (rather
than protein) of SphK1, SphK2, sphingosine 1-phosphate receptor 1 (S1P1), or sphingosine 1-
phosphate receptor 2 (S1P2) and 10 year relapse free survival of non-classified breast cancer (BCA)
patients. High SphK1 mRNA in tumors had no effect on 10 year relapse free disease survival, while
high SphK2mRNAwas found to have a positive impact in patients with non-classified, or basal type
BCA and those who had received adjuvant therapy. Lei et al. (8) also reported that high S1P1 mRNA
in tumors was associated with improved survival in patients with non-classified BCA and in those
receiving treatment, but had no effect on patients with basal cell type BCA. In addition, improved
survival was associated with high S1P2 mRNA in tumors from patients with non-classified BCA,
basal cell type BCA and those patients receiving treatment.
We suggest that the interpretation of these findings should be viewed with considerable caution.
In this regard, Kaplan-Meier plot analysis relating gene expression, i.e., mRNA transcript, with
prognosis does not consider the possibility thatmRNA transcript expressionmay not reflect specific
protein levels. Indeed, it is the protein itself that performs the signaling function, and not the
mRNA. In this regard, if the turnover of a particular protein is slow, its mRNA levels might be
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low. Therefore, a reciprocal relationship could exist between
mRNA and protein levels. In this case, interpretation of the
results by Lei et al. (8) would be completely reversed. For
instance, it could be concluded that high expression of S1P1
protein (low mRNA transcript) in BCA tumors is linked with
a poorer prognosis. Indeed, this was precisely the findings of
Watson et al. (9) where the estrogen receptor positive (ER+)
breast cancer tumors of a population of 304 patients was
analyzed. In this respect, high protein expression of S1P1 or
SphK1 (detected using immunohistochemical staining with anti-
S1P1 antibody or anti-SphK1 antibody) in tumors was associated
with earlier disease recurrence and reduced disease specific
survival times. The difference for S1P1 is not trivial with mean
disease recurrence and disease specific survival times being
shortened by between 3 and 8 years, respectively.
In addition, a relationship with poor prognosis was evident
for both membrane and cytoplasmic localized S1P1; the latter
probably reflects receptors that have been endocytosed in
response to S1P, and which are capable of persistent signaling
(10). In contrast, combined high nuclear localized S1P2 and c-
Src protein expression in tumors is associated with increased
disease specific survival times (11). Indeed, a thorough analysis of
the impact of S1P receptor sub-types on breast cancer prognosis
should also consider sub-cellular localization and this can only
be performed using analysis of protein with validated anti-S1P
receptor antibodies. There is a very substantial body of evidence
that demonstrates that S1P1 promotes tumorigenesis through, for
example, enhanced cell survival, migration, and angiogensis (7).
The role of S1P2 in cancer is more controversial with evidence
that it can either promote or inhibit tumorigenesis (12, 13). To
rationalize these findings, we have proposed that the positive
and negative function of the S1P2 receptor in cancer might be
dependent on its sub-cellular localization (14).
Patient stratification based on ER, progesterone receptor
and HER2 status is also important. This is exemplified
by the finding that high expression of SphK1 protein in
tumors actually increases disease specific survival times in
ER+/HER2+ patients. Indeed, high expression of SphK1 induces
a desensitization/tolerance to HER2-mediated signaling in
ER+/HER2+ breast cancer cells (15).
S1P RECEPTOR-DEPENDENT
MECHANISMS
To provide a mechanistic explanation for the clinical findings,
Lei et al. (8) reported the inhibition of colony formation by
MCF-7 cells (ER+) or triple negative MDA-MB-231 cells in
response to treatment with S1P (4–10µM) for 2 weeks. Using
shRNA knockdown of either S1P1 or S1P2 in MCF-7 and
MDA-MB-231 cells, the authors showed that the inhibitory
effect of S1P on colony formation was enhanced in both cell
types upon S1P2 knockdown whereas S1P1 knockdown reduced
the effect in MDA-MB-231 cells and was without effect in
MCF-7 cells. However, there was no evidence presented to
indicate that the effect of S1P on colony formation actually
reflects an inhibition of growth assessed by, for instance, cell-
cycle analysis. This is critically important in order to validate
the conclusions, because S1P stimulates migration via S1P3
(15) and S1P1 (16). In contrast, the S1P2 receptor has been
linked with inhibition of cell migration (17). Therefore, the
findings by Lei et al. (8) regarding the effect of shRNA
knockdown of S1P2 are in fact consistent with a relief of
the inhibitory constraint of S1P2 on the migration of MCF-
7 and MDA-MB-231 cells in response to added S1P. This
would reduce colony formation by enhancing dispersal and
thereby preventing colony residency. The knockdown of S1P1
in reducing the inhibitory effect of S1P on colony formation of
MDA-MB-231 cells is consistent with ablation of the positive
effect of S1P1 on migration, which would enhance colony
formation/residency. Thus, colony formation (without more
extensive cell cycle analysis and assessment of migration)
does not provide confirmation that S1P inhibits tumorigenesis
in vitro. The effect of treatment with S1P for 2 weeks
on S1P receptor expression was also not examined by Lei
et al. (8).
The major functional S1P receptor type in MCF-7 cells is,
in fact, the S1P3 receptor which induces activation of the ERK-
1/2 pathway via transactivation of the EGF receptor to promote
migration (18, 19). S1P3 expression/function was not analyzed
by Lei et al. (8). Furthermore, the EGF receptor kinase is
positively linked with tumorigenesis and this is a rationale for
the use of EGF receptor kinase inhibitors for the treatment of
cancer. Therefore, in contrast to the authors’ conclusions, these
prior published findings strongly implicate S1P in promoting
breast cancer tumorigenesis via an EGF receptor-dependent
mechanism. Finally, the study by Lei et al. (8) takes no account of
the other responses that S1P regulates through its receptors and
which are of relevance to cancer, such as migration, angiogenesis
and chemo-resistance.
CONCLUSION
We conclude that meaningful analysis of the impact of tumor
S1P receptor sub-type expression on the survival of breast cancer
patients requires analysis of actual protein levels and not mRNA.
There is also a need to stratify patient cohorts to consider for
instance, ER and HER2 expression. In addition, the effects of S1P
on colony formation of MCF-7 and MDA-MB-231 cells requires
analysis of cell cycle progression and migration with respect
to the function of different S1P receptor sub-types. Moreover,
a comprehensive analysis of the protein expression of all S1P
receptors in the breast cancer cells studied and their individual
biological functions should be interrogated. This is important
as it is unknown whether, for instance, knockdown of S1P1
and/or S1P2 has an effect on the expression of the other S1P
receptors and whether there is redundancy and/or divergent
biological functions of these receptors. Indeed, this appears to
be the case as evidenced by lack of effect of S1P1 knockdown
in MCF7 cells, where S1P3 may play a more prominent role.
Finally, Lei et al. (8) conclude that breast cancer could be
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treated with S1P1 specific agonists, but provide no in vivo
data to support this. In contrast, we argue that the weight
of published evidence clearly suggests that such S1P1 specific
agonists have the potential to reduce disease specific survival
times for breast cancer patients which is counterproductive in
terms of therapy.
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